Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSep1 neonatal sepsis antibiotic regimen trial
PACTR202208856270989Phase 4Recruiting
- Sponsor
- GARDP
- Start
- Oct 2022
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of ampicillin, gentamicin, cefotaxime, ceftriaxone, fosfomycin and 5 more in neonatal sepsis (10 arms), sponsored by GARDP. Primary endpoint: Fosfomycin and flomoxef population pharmacokinetic parameters. Started Oct 2022; status: recruiting.
02
Drugs
ampicillingentamicincefotaximeceftriaxonefosfomycin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on PACTR202208856270989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202208856270989.